Performance of T-SPOT.TBTM (TS-TB) and QuantiFERON TB Gold-In tube (QFT-IT) assays was evaluated for detection of M. tuberculosis (Mtb) infection in patients with suspected extra-pulmonary or smear-negative pulmonary tuberculosis (TB) in a low prevalence country. Twenty-one out of 35 patients were affected by active TB. Mtb culture isolation was achieved in 76% of cases. Tuberculin skin testing (TST), TS-TB, and QFT-IT yielded a positive result in 67%, 95% and 81% of cases, respectively. Agreement of interferon-y release assays and TST was 70% (K=0.18 for TS-TB; K=0.46 for QFT-IT). Increased sensitivity of blood assays (>80%) improved diagnostic evaluation of difficult TB cases.
Successful control of tuberculosis (TB) relies on prompt detection and treatment of active disease. While smear-positive pulmonary TB is readily diagnosed, bacteriological confirmation is often not possible in smear-negative cases. Conventional staining for acid-fast bacilli (AFB) and M tuberculosis (Mtb) culture are insensitive or time-consuming (l). In addition, nucleic acid amplification procedures, while providing quick and specific results, are considerably less sensitive than culture in AFB-negative cases (l). The IOO-yr old tuberculin skin test (TST) remains the most widely used tool in clinical practice in the evaluation of TB infection despite its poor sensitivity and specificity (l). Advances in scientific knowledge have recently led to the development of blood tests based on the principle of detecting the release of interferon (IFN)-y by memory effector T cells upon in vitro stimulation with two Mtbspecific RD (region of difference )-1 encoded antigens, ESAT (early secretory antigen)-6 and CFP (culture filtrate protein)-IO (2) . These assays are more specific than TST, as RD-l genes are not shared by most environmental mycobacteria and M bovis BCG, correlate better with Mtb exposure, and are more sensitive in detecting active TB cases, at least in low prevalence settings (3) (4) (5) . The aim of the present note is to address the usefulness of two IGRAs, i.e., T-SPOT.TB™ (TS-TB, Oxford Immunotech, Abingdon, UK) and QuantiFERON-TB GOLD In tube (QFT-IT), as surrogate tools for detection of Mtb infection in difficult-to-manage TB cases in clinical practice in a referral center in a low prevalence setting. 
Patients with extra-pulmonary TB
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Note that among TB cases 4 extra-community (EC)-born patients were included who came from high TB prevalence countries. All ofthem had been in Italy for more than 5 years, and 3 cases were BCG-vaccinated (last vaccination at least 10 years previous to the study). 
C) Patients with diseases other than TB
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Study design and results
Twenty-eight consecutive human immunodeficiency virus (HIV)-negative patients with suspected AFB-negative pulmonary TB were enrolled over a one-year period. Patients presented with fever and respiratory symptoms for more than 2 weeks, three consecutive AFB-negative sputa and compatible chest X-ray findings, including pulmonary fibroexudative lesions (n=IO, 28%), nodules (n=6, 17%), alveolar infiltrates (n=9, 26%), and miliary shadowing (n=3, 8.5%). Cavitation was present in 5 cases (14%). Seven additional HIV-negative patients with AFB-negative lymphocytic pleural effusion (n=3) or cervical adenopathy of unknown ongm (n=4) were also included. Performance of TS-TB and QFT-IT as surrogate tools for detection of TB infection was evaluated in comparison with conventional TST. Overall, the study population included 31 Italians and 4 patients from high TB prevalence countries (Romania and Ukraine). Mean age±SD was 49±19 yrs (males=17; smokers=13). Co-morbidities included chronic obstructive pulmonary disease (n=5) and diabetes (n=2). TST was carried out using the Mantoux method (5 IU of purified protein derivative) and read within 72 h. TST positive results were defined according to the American Thoracic Society standards (1) . Blood samples were obtained for IFN-y release (1) . Final diagnosis was confirmed by Mtb culture isolation in 16 cases (76%), histology in 1 case (4.7%), nucleic acid amplification (Probetec ET, BD) in 2 patients (9.5%) and on response to treatment in 2 cases (9.5%). TST scored positive results in 14 patients (67%), TS-TB and QFT-IT in 20 (95%) and 17 (81%) cases, respectively. QFT-IT yielded an indeterminate result in one patient (5%) due to high background. While no significant differences were recorded between TS-TB and QFT-IT performance Table  I . Sensitivity, specificity and predictive values of IGRAs are shown in Table II .
DISCUSSION
The present study reports the results of the performance ofIGRAs for detection ofTB infection in a selected patient population suspected of extrapulmonary or AFB-negative pulmonary TB in a referral center in a low prevalence country. Increased sensitivity of IGRAs (>80% as compared to 66% of TST), resulted in improved diagnostic evaluation of difficult TB cases with falsely negative TST results (30% in our case series). Decision to start anti-TB treatment was carefully based on the evaluation of all available medical data, including IGRAs, that enabled a clinical diagnosis while microbiological or histology tests were pending. Although IGRAs did not help in differentiating active from latent TB, as this distinction was based on clinical judgement, their relative high NPV suggests the adjunctive role that these tests, in spite of TST (NPV=60% in our case series), may have in excluding the diagnosis of active TB. Consistent with previous reports, assays detecting secretion of IFN-y upon stimulation with RD-l antigens for diagnosis of active TB have a sensitivity >80%. However, specificity (45-70%), PPV (65-85%), and NPV (55-90%) were highly variable due to different criteria for patient selection and diagnosis of active TB (3) (4) (5) (6) . In our opinion, this is quite an intriguing topic as to date there has been no full agreement concerning the usefulness of IGRAs, in spite of, or in addition to TST, in the preliminary evaluation of active TB cases. In addition, high rates of IGRAs positive results may limit their usefulness in areas with high TB prevalence The US Centers for Disease Control and Prevention (CDC) recommend the use ofQFT-G (the predecessor ofQFT-IT) in all circumstances in which the TST is currently used, including diagnosis of active TB (7) ; however, the real impact and cost-effectiveness of IGRAs in such a clinical context are not well established in countries with different TB prevalence. In this issue, in ·the European setting the National Collaborating Centre for Chronic Conditions suggests IGRAs (with no mention of a given test format) may have a role in selected cases of suspected TB to rule out infection with Mtb (8).
In conclusion, despite our study not providing additional information to current knowledge in the field, it however encourages the use of IGRAs as powerful tools for detection ofTB infection in TSTnegative patients with a high clinical suspicion of extra-pulmonary or AFB-negative pulmonary TB. This occurred in our series in six TST-negative patients who tested positive by at least one IGRA, including two cases of cavitary pulmonary TB and 4 additional cases of extra-pulmonary disease (i.e., two patients with pleurisy and two patients with cervical adenopathy). The aim of the present report is to provide a picture of how IGRAs may work in routine clinical practice when applied to selected patient populations for addressing specific questions. Indeed, since the rapid diffusion of IGRAs in clinical practice, one of the main needs of clinicians is to know how to use these innovative, but also expensive, assays in settings in which evidencebased information is still limited. Despite our study being restricted to a small number of patients, we found no significant differences in performance between the two formats of blood assays used. Most importantly, as in our series only a minority of patients was represented by EC patients, a major effort is requested in this field for assessing usefulness of IGRAs in spite of TST for detection of TB infection in the management of difficult TB cases among patients from high prevalence areas where BCG vaccination is widely applied. In addition, as recent studies suggest, application of IGRAs in biological samples representative of the infection site, has also to be encouraged as a diagnostic challenge and for discriminating active from latent TB (9-10).
